VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Verrica Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $16.71M | $16.15M | $15.29M | $11.88M | $6.41M | $6.76M | $6.57M | $8.13M | $12.78M | $7.89M | $4.66M | $2.79M | 55.1% | +160.9% |
| License and collaboration revenue | $13.61M | $21.01M | $20.29M | $18.95M | $8.30M | $415.00K | $992.00K | – | – | – | – | – | 44.9% | +64.0% |
| Collaboration [Member] | – | – | – | – | – | $415.00K | $992.00K | $1.09M | $1.13M | $1.02M | $466.00K | $412.00K | – | – |
| License and Collaboration Revenue, Commercial Supply and Development | – | – | $2.30M | – | – | – | $1.00M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Verrica Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.